WO1999038493A1 - Microparticle inhalation formulations - Google Patents
Microparticle inhalation formulations Download PDFInfo
- Publication number
- WO1999038493A1 WO1999038493A1 PCT/US1998/027922 US9827922W WO9938493A1 WO 1999038493 A1 WO1999038493 A1 WO 1999038493A1 US 9827922 W US9827922 W US 9827922W WO 9938493 A1 WO9938493 A1 WO 9938493A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- surfactant
- formulation
- drug
- aerosol formulation
- propellant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/797—Lipid particle
- Y10S977/798—Lipid particle having internalized material
- Y10S977/799—Containing biological material
- Y10S977/801—Drug
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/84—Manufacture, treatment, or detection of nanostructure
- Y10S977/89—Deposition of materials, e.g. coating, cvd, or ald
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98965051A EP1051154A1 (en) | 1998-01-30 | 1998-12-30 | Microparticle inhalation formulations |
JP2000529227A JP2002501885A (en) | 1998-01-30 | 1998-12-30 | Formulation for inhalation of fine particles |
CA002319100A CA2319100C (en) | 1998-01-30 | 1998-12-30 | Microparticle inhalation formulations |
IL13747298A IL137472A (en) | 1998-01-30 | 1998-12-30 | Microparticle inhalation formulations |
KR1020007008094A KR20010040402A (en) | 1998-01-30 | 1998-12-30 | Microparticle Inhalation Formulations |
AU20244/99A AU756464B2 (en) | 1998-01-30 | 1998-12-30 | Microparticle inhalation formulations |
SE0002643A SE0002643L (en) | 1998-01-30 | 2000-07-13 | Inhalation preparations containing microparticles |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/016,265 US6086376A (en) | 1998-01-30 | 1998-01-30 | Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant |
US09/016,265 | 1998-01-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999038493A1 true WO1999038493A1 (en) | 1999-08-05 |
Family
ID=21776235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/027922 WO1999038493A1 (en) | 1998-01-30 | 1998-12-30 | Microparticle inhalation formulations |
Country Status (10)
Country | Link |
---|---|
US (1) | US6086376A (en) |
EP (1) | EP1051154A1 (en) |
JP (2) | JP2002501885A (en) |
KR (1) | KR20010040402A (en) |
CN (1) | CN1155367C (en) |
AU (1) | AU756464B2 (en) |
CA (1) | CA2319100C (en) |
IL (1) | IL137472A (en) |
SE (1) | SE0002643L (en) |
WO (1) | WO1999038493A1 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000015262A1 (en) * | 1998-09-14 | 2000-03-23 | Inhale Therapeutic Systems, Inc. | Dry powder active agent pulmonary delivery |
WO2000027363A1 (en) | 1998-11-12 | 2000-05-18 | Elan Pharma International Ltd. | Aerosols comprising nanoparticle drugs |
WO2002043702A2 (en) * | 2000-11-30 | 2002-06-06 | Vectura Limited | Pharmaceutical compositions for inhalation |
US6835396B2 (en) | 2001-09-26 | 2004-12-28 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion lyophilization |
EP1920763A1 (en) * | 2000-11-30 | 2008-05-14 | Vectura Limited | Pharmaceutical compositions for inhalation |
WO2008152398A2 (en) * | 2007-06-14 | 2008-12-18 | Cipla Limited | Formulations for inhalation |
WO2009095681A2 (en) * | 2008-02-01 | 2009-08-06 | Vectura Limited | Suspension formulations |
US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
US8097282B2 (en) | 1995-02-24 | 2012-01-17 | Alkermes Pharma Ireland Limited | Methods of administering liquid droplet aerosols of nanoparticulate drugs |
US8580306B2 (en) | 2000-11-30 | 2013-11-12 | Vectura Limited | Particles for use in a pharmaceutical composition |
US8722091B2 (en) | 2001-09-26 | 2014-05-13 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion lyophilization |
US8877162B2 (en) | 2000-05-10 | 2014-11-04 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery |
US9421166B2 (en) | 2001-12-19 | 2016-08-23 | Novartis Ag | Pulmonary delivery of aminoglycoside |
US9554993B2 (en) | 1997-09-29 | 2017-01-31 | Novartis Ag | Pulmonary delivery particles comprising an active agent |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US11090294B2 (en) | 2009-12-01 | 2021-08-17 | Glaxo Group Limited | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
US11116721B2 (en) | 2009-02-26 | 2021-09-14 | Glaxo Group Limited | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6465016B2 (en) * | 1996-08-22 | 2002-10-15 | Research Triangle Pharmaceuticals | Cyclosporiine particles |
US20020017295A1 (en) * | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
US6309623B1 (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
ATE259220T1 (en) | 1998-05-29 | 2004-02-15 | Skyepharma Canada Inc | MICROPARTICLES PROTECTED AGAINST HEAT AND METHOD FOR THE TERMINAL STEAM STERILIZATION OF SAME |
SK288117B6 (en) | 1998-11-20 | 2013-09-03 | Skyepharma Canada Inc. | Rapidly dispersing solid dry therapeutic dosage form |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
WO2001021154A2 (en) * | 1999-09-21 | 2001-03-29 | Rtp Pharma Inc. | Surface modified particulate compositions of biologically active substances |
US6962151B1 (en) * | 1999-11-05 | 2005-11-08 | Pari GmbH Spezialisten für effektive Inhalation | Inhalation nebulizer |
US6645467B2 (en) * | 1999-11-28 | 2003-11-11 | Scientific Development And Research, Inc. | Composition and method for decreasing upper respiratory airway resistance |
IT1317720B1 (en) * | 2000-01-07 | 2003-07-15 | Chiesi Farma Spa | DEVICE FOR THE ADMINISTRATION OF AEROSOL DOSED PRESSURIZED INPROPELLENT HYDROFLUOROALKANS. |
US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
GB0016876D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Novel formulation |
US20040081627A1 (en) * | 2000-10-09 | 2004-04-29 | Jinks Phillip A | Medicinal aerosol formulations |
US20030096013A1 (en) * | 2000-12-22 | 2003-05-22 | Jane Werling | Preparation of submicron sized particles with polymorph control |
US6607784B2 (en) * | 2000-12-22 | 2003-08-19 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
US6977085B2 (en) | 2000-12-22 | 2005-12-20 | Baxter International Inc. | Method for preparing submicron suspensions with polymorph control |
US6884436B2 (en) | 2000-12-22 | 2005-04-26 | Baxter International Inc. | Method for preparing submicron particle suspensions |
US7193084B2 (en) * | 2000-12-22 | 2007-03-20 | Baxter International Inc. | Polymorphic form of itraconazole |
US20040256749A1 (en) * | 2000-12-22 | 2004-12-23 | Mahesh Chaubal | Process for production of essentially solvent-free small particles |
US20050048126A1 (en) | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
DE50211045D1 (en) * | 2001-03-30 | 2007-11-22 | Jagotec Ag | MEDICAL AEROSOL FORMULATIONS |
US7112340B2 (en) * | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
US20030178022A1 (en) * | 2001-12-21 | 2003-09-25 | Chiesi Farmaceutici S.P.A. | Pressurized metered dose inhaler (PMDI) actuators and medicinal aerosol solution formulation products comprising therse actuators |
JP2005523905A (en) * | 2002-03-01 | 2005-08-11 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Formoterol ultrafine formulation |
JP3620842B2 (en) * | 2002-12-25 | 2005-02-16 | 孝之 阿部 | Polygonal barrel sputtering apparatus, polygonal barrel sputtering method, coated fine particles formed thereby, and method for producing coated fine particles |
US7511079B2 (en) * | 2003-03-24 | 2009-03-31 | Baxter International Inc. | Methods and apparatuses for the comminution and stabilization of small particles |
GB0323684D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
GB0323685D0 (en) * | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
DE10347994A1 (en) * | 2003-10-15 | 2005-06-16 | Pari GmbH Spezialisten für effektive Inhalation | Aqueous aerosol preparation |
US20050121025A1 (en) * | 2003-12-04 | 2005-06-09 | Gamard Stephan C.F. | Portable gas operating inhaler |
TWI262798B (en) * | 2003-12-31 | 2006-10-01 | Ind Tech Res Inst | Liposome and drug deliver system |
JP2007520555A (en) * | 2004-02-05 | 2007-07-26 | バクスター・インターナショナル・インコーポレイテッド | Dispersants prepared by use of self-stabilizing agents |
US8082735B2 (en) * | 2005-04-06 | 2011-12-27 | Massachusetts Institute Of Technology | Optimized fuel management system for direct injection ethanol enhancement of gasoline engines |
EP1712220A1 (en) * | 2005-04-15 | 2006-10-18 | PARI GmbH Spezialisten für effektive Inhalation | Pharmaceutical aerosol composition |
US8367734B1 (en) | 2005-08-11 | 2013-02-05 | Amphastar Pharmaceuticals Inc. | Stable epinephrine suspension formulation with high inhalation delivery efficiency |
US8426467B2 (en) | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
US8722736B2 (en) | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
GB0918149D0 (en) | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved medicinal aerosol formulation |
JP2013540827A (en) | 2010-10-29 | 2013-11-07 | ウエスタン ユニバーシティ オブ ヘルス サイエンシズ | Three-mixed preparation |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
GB201118232D0 (en) | 2011-10-21 | 2011-12-07 | M W Encap Ltd | Pharmaceutical composition |
US20170246187A1 (en) | 2014-08-28 | 2017-08-31 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
JP6417181B2 (en) * | 2014-10-10 | 2018-10-31 | 学校法人神奈川大学 | Emulsion composition for aerosol preparation and aerosol agent |
SG11201705069YA (en) * | 2014-12-26 | 2017-07-28 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
WO2017156380A1 (en) * | 2016-03-10 | 2017-09-14 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
US11559530B2 (en) | 2016-11-28 | 2023-01-24 | Lipocine Inc. | Oral testosterone undecanoate therapy |
US10315836B2 (en) * | 2017-10-19 | 2019-06-11 | Matthew James ZABLOSKI | Methods, uses, and apparatus for presenting and storing objects |
EP3706762A4 (en) | 2017-12-07 | 2021-09-01 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
WO2021236570A1 (en) * | 2020-05-18 | 2021-11-25 | Anovent Pharmaceutical (U.S.), Llc | Pharmaceutical formulation containing remdesivir and its active metabolites for dry powder inhalation |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991004011A1 (en) * | 1989-09-20 | 1991-04-04 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
WO1991011495A1 (en) * | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Novel vehicle gas mixtures and their use in medical preparations |
EP0535567A1 (en) * | 1991-10-01 | 1993-04-07 | B. Braun Melsungen AG | Liposomes containing volatile inhalation anaesthetics, their preparation and their use |
WO1993015741A1 (en) * | 1992-02-06 | 1993-08-19 | Glaxo Group Limited | Medicaments |
EP0634166A1 (en) * | 1993-07-15 | 1995-01-18 | Hoechst Aktiengesellschaft | Drug compositions containing coated, poorly watersoluble drugs for use in pharmaceutical inhalation forms and method to produce them |
US5492688A (en) * | 1993-04-28 | 1996-02-20 | The Center For Innovative Technology | Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent |
WO1996018384A1 (en) * | 1994-12-10 | 1996-06-20 | Glaxo Group Limited | Propellant mixture for aerosol formulation |
WO1996019197A1 (en) * | 1994-12-22 | 1996-06-27 | Astra Aktiebolag | Aerosol formulations of peptides and proteins |
WO1996019198A1 (en) * | 1994-12-22 | 1996-06-27 | Astra Aktiebolag | Aerosol drug formulations |
WO1997044012A1 (en) * | 1996-05-17 | 1997-11-27 | Andaris Limited | Formulation comprising microparticles, for inhalation |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7708731A (en) * | 1976-08-13 | 1978-02-15 | Montedison Spa | PROCESS FOR THE PREPARATION OF NEW DRIVER COMPOSITIONS FOR AEROSOLS. |
US5225183A (en) * | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
GB8908250D0 (en) * | 1989-04-12 | 1989-05-24 | Fisons Plc | Formulations |
GB9002327D0 (en) * | 1990-02-02 | 1990-04-04 | Univ Sheffield | Optical elements |
US5118494A (en) * | 1990-03-23 | 1992-06-02 | Minnesota Mining And Manufacturing Company | Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
US5126123A (en) * | 1990-06-28 | 1992-06-30 | Glaxo, Inc. | Aerosol drug formulations |
CA2094266C (en) * | 1990-10-18 | 1999-06-01 | Robert K. Schultz | Aerosol formulations of beclomethasone-17,21-dipropionate |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5552160A (en) * | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
US5182097A (en) * | 1991-02-14 | 1993-01-26 | Virginia Commonwealth University | Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
ATE134509T1 (en) * | 1991-06-10 | 1996-03-15 | Schering Corp | HYDROCHLOROFLUOROCARBON-FREE AEROSOL FORMULATIONS |
IL103238A (en) * | 1991-09-25 | 1995-07-31 | Fisons Plc | Pressurised aerosol compositions |
US5674471A (en) * | 1991-12-12 | 1997-10-07 | Glaxo Group Limited | Aerosol formulations containing P134a and salbutamol |
IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
US5683676A (en) * | 1991-12-12 | 1997-11-04 | Glaxo Group Limited | Canister containing aerosol formulations containing P134a and particulate medicaments |
CA2455115C (en) * | 1991-12-12 | 2008-05-27 | Glaxo Group Limited | Pharmaceutical aerosol formulation |
US5202110A (en) * | 1992-01-22 | 1993-04-13 | Virginia Commonwealth University | Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants |
MX9304585A (en) * | 1992-07-31 | 1994-03-31 | Glaxo Group Ltd | PHARMACEUTICAL FORMULATION IN AEROSOL, CAN SUITABLE TO RELEASE THE FORMULATION AND INHALER OF DOSE DOSE THAT COMPRISES THE CAN. |
AU679510B2 (en) * | 1993-03-17 | 1997-07-03 | Minnesota Mining And Manufacturing Company | Aerosol formulation containing a diol-diacid derived dispersing aid |
US5635159A (en) * | 1994-08-26 | 1997-06-03 | Abbott Laboratories | Aerosol drug formulations containing polyglycolyzed glycerides |
EE04004B1 (en) * | 1995-04-14 | 2003-04-15 | Glaxo Wellcome Inc. | Fluticasone propionate metered dose inhaler |
CA2361954C (en) * | 1995-04-14 | 2003-07-08 | Smithkline Beecham Corporation | Metered dose inhaler for albuterol |
BR9604977A (en) * | 1995-04-14 | 1998-06-09 | Glaxo Wellcome Inc | Metered dose inhaler metered dose inhaler system and use |
US5635161A (en) * | 1995-06-07 | 1997-06-03 | Abbott Laboratories | Aerosol drug formulations containing vegetable oils |
-
1998
- 1998-01-30 US US09/016,265 patent/US6086376A/en not_active Expired - Lifetime
- 1998-12-30 CN CNB988133849A patent/CN1155367C/en not_active Expired - Fee Related
- 1998-12-30 WO PCT/US1998/027922 patent/WO1999038493A1/en not_active Application Discontinuation
- 1998-12-30 KR KR1020007008094A patent/KR20010040402A/en not_active Application Discontinuation
- 1998-12-30 AU AU20244/99A patent/AU756464B2/en not_active Ceased
- 1998-12-30 IL IL13747298A patent/IL137472A/en not_active IP Right Cessation
- 1998-12-30 CA CA002319100A patent/CA2319100C/en not_active Expired - Fee Related
- 1998-12-30 EP EP98965051A patent/EP1051154A1/en not_active Ceased
- 1998-12-30 JP JP2000529227A patent/JP2002501885A/en not_active Withdrawn
-
2000
- 2000-07-13 SE SE0002643A patent/SE0002643L/en not_active Application Discontinuation
-
2010
- 2010-06-04 JP JP2010128713A patent/JP2010248206A/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991004011A1 (en) * | 1989-09-20 | 1991-04-04 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
WO1991011495A1 (en) * | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Novel vehicle gas mixtures and their use in medical preparations |
EP0535567A1 (en) * | 1991-10-01 | 1993-04-07 | B. Braun Melsungen AG | Liposomes containing volatile inhalation anaesthetics, their preparation and their use |
WO1993015741A1 (en) * | 1992-02-06 | 1993-08-19 | Glaxo Group Limited | Medicaments |
US5492688A (en) * | 1993-04-28 | 1996-02-20 | The Center For Innovative Technology | Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent |
EP0634166A1 (en) * | 1993-07-15 | 1995-01-18 | Hoechst Aktiengesellschaft | Drug compositions containing coated, poorly watersoluble drugs for use in pharmaceutical inhalation forms and method to produce them |
WO1996018384A1 (en) * | 1994-12-10 | 1996-06-20 | Glaxo Group Limited | Propellant mixture for aerosol formulation |
WO1996019197A1 (en) * | 1994-12-22 | 1996-06-27 | Astra Aktiebolag | Aerosol formulations of peptides and proteins |
WO1996019198A1 (en) * | 1994-12-22 | 1996-06-27 | Astra Aktiebolag | Aerosol drug formulations |
WO1997044012A1 (en) * | 1996-05-17 | 1997-11-27 | Andaris Limited | Formulation comprising microparticles, for inhalation |
Cited By (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8097282B2 (en) | 1995-02-24 | 2012-01-17 | Alkermes Pharma Ireland Limited | Methods of administering liquid droplet aerosols of nanoparticulate drugs |
US9554993B2 (en) | 1997-09-29 | 2017-01-31 | Novartis Ag | Pulmonary delivery particles comprising an active agent |
AP1374A (en) * | 1998-09-14 | 2005-02-28 | Inhale Therapeutic Syst | Aerosolizable particles resistant to hygroscopic growth. |
WO2000015262A1 (en) * | 1998-09-14 | 2000-03-23 | Inhale Therapeutic Systems, Inc. | Dry powder active agent pulmonary delivery |
US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
WO2000027363A1 (en) | 1998-11-12 | 2000-05-18 | Elan Pharma International Ltd. | Aerosols comprising nanoparticle drugs |
US6811767B1 (en) | 1998-11-12 | 2004-11-02 | Elan Pharma International Limited | Liquid droplet aerosols of nanoparticulate drugs |
EP2263652A1 (en) * | 1998-11-12 | 2010-12-22 | Elan Pharma International Limited | Aerosols comprising nanoparticle drugs |
EP2851067A1 (en) | 2000-05-10 | 2015-03-25 | Novartis AG | Phospholipid-based powders for drug delivery |
US8877162B2 (en) | 2000-05-10 | 2014-11-04 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery |
US9439862B2 (en) | 2000-05-10 | 2016-09-13 | Novartis Ag | Phospholipid-based powders for drug delivery |
AU2002222115B2 (en) * | 2000-11-30 | 2006-09-28 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
EP1920763A1 (en) * | 2000-11-30 | 2008-05-14 | Vectura Limited | Pharmaceutical compositions for inhalation |
US10188612B2 (en) | 2000-11-30 | 2019-01-29 | Vectura Limited | Pharmaceutical compositions for inhalation |
US9962338B2 (en) | 2000-11-30 | 2018-05-08 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
US7736670B2 (en) | 2000-11-30 | 2010-06-15 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
US10449161B2 (en) | 2000-11-30 | 2019-10-22 | Vectura Limited | Pharmaceutical compositions for inhalation |
EP2283817A1 (en) * | 2000-11-30 | 2011-02-16 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
EP2283818A1 (en) * | 2000-11-30 | 2011-02-16 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
EP2298285A3 (en) * | 2000-11-30 | 2011-07-27 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
EP2298279A3 (en) * | 2000-11-30 | 2011-08-03 | Vectura Limited | Pharmaceutical compositions for inhalation |
US8048451B2 (en) | 2000-11-30 | 2011-11-01 | Vectura Limited | Pharmaceutical compositions for inhalation |
US10238601B2 (en) | 2000-11-30 | 2019-03-26 | Vectura Limited | Particles for use in a pharmaceutical composition |
US10973771B2 (en) | 2000-11-30 | 2021-04-13 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
US8303991B2 (en) | 2000-11-30 | 2012-11-06 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
US8580306B2 (en) | 2000-11-30 | 2013-11-12 | Vectura Limited | Particles for use in a pharmaceutical composition |
US9931304B2 (en) | 2000-11-30 | 2018-04-03 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
WO2002043702A3 (en) * | 2000-11-30 | 2002-10-17 | Vectura Ltd | Pharmaceutical compositions for inhalation |
US8932635B2 (en) | 2000-11-30 | 2015-01-13 | Vectura Limited | Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation |
US8956661B2 (en) | 2000-11-30 | 2015-02-17 | Vectura Limited | Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof |
WO2002043701A3 (en) * | 2000-11-30 | 2002-10-17 | Vectura Ltd | Method of making particles for use in a pharmaceutical composition |
WO2002043702A2 (en) * | 2000-11-30 | 2002-06-06 | Vectura Limited | Pharmaceutical compositions for inhalation |
EP2283817B1 (en) | 2000-11-30 | 2016-05-18 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US8722091B2 (en) | 2001-09-26 | 2014-05-13 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion lyophilization |
US6835396B2 (en) | 2001-09-26 | 2004-12-28 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion lyophilization |
US9421166B2 (en) | 2001-12-19 | 2016-08-23 | Novartis Ag | Pulmonary delivery of aminoglycoside |
WO2008152398A3 (en) * | 2007-06-14 | 2009-11-12 | Cipla Limited | Formulations for inhalation |
WO2008152398A2 (en) * | 2007-06-14 | 2008-12-18 | Cipla Limited | Formulations for inhalation |
US9011923B2 (en) | 2008-02-01 | 2015-04-21 | Innovata Biomed Limited | Suspension formulations |
WO2009095681A3 (en) * | 2008-02-01 | 2010-05-14 | Vectura Limited | Suspension formulations |
WO2009095681A2 (en) * | 2008-02-01 | 2009-08-06 | Vectura Limited | Suspension formulations |
US11116721B2 (en) | 2009-02-26 | 2021-09-14 | Glaxo Group Limited | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol |
US11090294B2 (en) | 2009-12-01 | 2021-08-17 | Glaxo Group Limited | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Also Published As
Publication number | Publication date |
---|---|
EP1051154A1 (en) | 2000-11-15 |
CA2319100C (en) | 2008-05-27 |
KR20010040402A (en) | 2001-05-15 |
US6086376A (en) | 2000-07-11 |
AU2024499A (en) | 1999-08-16 |
JP2002501885A (en) | 2002-01-22 |
CA2319100A1 (en) | 1999-08-05 |
CN1155367C (en) | 2004-06-30 |
IL137472A (en) | 2005-08-31 |
CN1283989A (en) | 2001-02-14 |
IL137472A0 (en) | 2001-07-24 |
AU756464B2 (en) | 2003-01-16 |
JP2010248206A (en) | 2010-11-04 |
SE0002643D0 (en) | 2000-07-13 |
SE0002643L (en) | 2000-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2319100C (en) | Microparticle inhalation formulations | |
ES2289832T3 (en) | PHARMACEUTICAL AEROSOL COMPOSITION CONTAINING HFA 227 AND HFA 134A. | |
JP3210012B2 (en) | Medicine | |
KR101926060B1 (en) | Compositions for respiratory delivery of active agents and associated methods and systems | |
ES2234266T3 (en) | MEDICAL FORMULATIONS FOR AEROSOLS. | |
ES2182351T5 (en) | PHARMACEUTICAL COMPOSITION IN AEROSOL. | |
JP3468767B2 (en) | Medicine | |
JP2001511160A (en) | Aerosol formulation for medical use | |
IL135126A (en) | Perforated microparticles and methods of use and preparation thereof | |
JP2017505789A5 (en) | ||
AU763945B2 (en) | Oil-core compositions for the sustained release of hydrophobic drugs | |
Sinswat et al. | Nebulization of nanoparticulate amorphous or crystalline tacrolimus–single-dose pharmacokinetics study in mice | |
US10744098B2 (en) | Spray-dried solid-in-oil-in-water dispersions for inhalation of active pharmaceutical ingredients | |
US20040213837A1 (en) | Oil-core compositions for the sustained release of hydrophobic drugs | |
ES2275778T3 (en) | SOLUBILIZATION OF PHARMACOS IN HFA PROPULSORS THROUGH EMULSIONS. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98813384.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 20244/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 00026435 Country of ref document: SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 137472 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007008094 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2319100 Country of ref document: CA Ref document number: 2319100 Country of ref document: CA Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2000 529227 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998965051 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 00026435 Country of ref document: SE |
|
WWP | Wipo information: published in national office |
Ref document number: 1998965051 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007008094 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 20244/99 Country of ref document: AU |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020007008094 Country of ref document: KR |